ICI like Nivolumab, Pembrolizumab (anti-PD-1), Atezolizumab, Avelumab (anti-PD-L1), and Ipilimumab (anti-CTLA-4) block these inhibitory checkpoints and enable T-cells to attack cancer cells (9, 81, 82). This evidence concerns the gene CD274 and cancer.